OncoMatch/Clinical Trials/NCT05830123
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
Is NCT05830123 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HS-20093 for osteosarcoma.
Treatment: HS-20093 — HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with relapsed or refractory osteosarcoma and other sarcomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Osteosarcoma
Sarcoma
Biomarker criteria
Excluded: CD276 prior B7-H3 targeted therapy
Previous or current treatment with B7-H3 targeted therapy
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic treatment — first-line
progressed upon first-line systemic treatment
Cannot have received: B7-H3 targeted therapy
Previous or current treatment with B7-H3 targeted therapy
Cannot have received: cytotoxic chemotherapy
Exception: within 14 days prior to the first scheduled dose of HS-20093
Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093
Cannot have received: monoclonal antibody
Exception: within 28 days prior to the first scheduled dose of HS-20093
Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093
Cannot have received: radiation therapy
Exception: limited field of radiation for palliation within 2 weeks, more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093
Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093
Cannot have received: major surgery
Exception: within 4 weeks of the first dose of HS-20093
Major surgery within 4 weeks of the first dose of HS-20093.
Lab requirements
Blood counts
Adequate bone marrow reserve required
Kidney function
No hepatorenal syndrome
Liver function
No hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis
Cardiac function
No evidence of cardiovascular risk; No severe, uncontrolled or active cardiovascular diseases
Inadequate bone marrow reserve or organ dysfunction; Evidence of cardiovascular risk; Severe, uncontrolled or active cardiovascular diseases; Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify